CanSino Biologics Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CASBF research report →
Companywww.cansinotech.com
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N.
- CEO
- Xuefeng Yu
- IPO
- 2020
- Employees
- 1,105
- HQ
- Tianjin, CN
Price Chart
Valuation
- Market Cap
- $1.36B
- P/E
- -15284.70
- P/S
- 10.14
- P/B
- 3.12
- EV/EBITDA
- 84.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.88%
- Op Margin
- -0.16%
- Net Margin
- -0.09%
- ROE
- -0.02%
- ROIC
- 0.01%
Growth & Income
- Revenue
- $1.03B · 25.12%
- Net Income
- $27.15M · 107.17%
- EPS
- $0.11 · 107.19%
- Op Income
- $-113,129,268
- FCF YoY
- 75.60%
Performance & Tape
- 52W High
- $6.99
- 52W Low
- $3.20
- 50D MA
- $3.86
- 200D MA
- $4.93
- Beta
- 1.16
- Avg Volume
- 51
Get TickerSpark's AI analysis on CASBF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CASBF Coverage
We haven't published any research on CASBF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CASBF Report →